Pain Perception: Lidocaine Rate/Temp/Buffer

NCT02823002 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2024-03-15

No results posted yet for this study

Summary

This study will collect data from multiple academic institutions. The primary objective for part A of this study is to determine the impact of anesthetic injection rate and temperature on pain perception during dermatologic procedures, and the objective for the part B of this study is to determine if buffering of the anesthetic solution alters pain perception.

This study is a pilot study designed to determine feasibility of these procedures.

Conditions

Interventions

PROCEDURE

Slow, Room Temperature Injection

The room temperature local anesthetic agent will be administered by slow infiltration.

PROCEDURE

Rapid, Room Temperature Injection

The room temperature local anesthetic agent will be administered by rapid infiltration.

PROCEDURE

Slow, Warm Temperature Injection

The warmed local anesthetic agent will be administered by slow infiltration.

PROCEDURE

Rapid, Warm Temperature Injection

The warmed local anesthetic agent will be administered by rapid infiltration.

PROCEDURE

Buffered Injection

One side of the body will be randomized to receive an injection of the buffered agent, while the contralateral side will be assigned to receive an injection of the unbuffered anesthetic agent.

PROCEDURE

Non-Buffered Injection

One side of the body will be randomized to receive an injection of the buffered agent, while the contralateral side will be assigned to receive an injection of the unbuffered anesthetic agent.

DRUG

Lidocaine

Injectable lidocaine solution (Lidocaine Hydrochloride and Epinephrine)

DRUG

Buffer

Sodium Bicarbonate

Sponsors & Collaborators

Principal Investigators

  • Murad Alam, MD · Northwestern University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2025-01-31
Completion
2025-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02823002 on ClinicalTrials.gov